A new publication involving cetrorelix appeared on October 19, 2026. The study, titled "Oral gonadotropin-releasing hormone antagonists versus injectable cetrorelix for luteinizing hormone surge prevention in donor in vitro fertilization cycles: A retrospective cohort study of efficacy, embryology, and stimulation dynamics," was published in the International Journal of Gynaecology and Obstetrics, the official organ of the International Federation of Gynaecology and Obstetrics.
The publication is described as a retrospective cohort study. It examines oral gonadotropin-releasing hormone antagonists compared with injectable cetrorelix in the context of donor in vitro fertilization cycles. The title indicates the study addresses luteinizing hormone surge prevention, embryology, and stimulation dynamics as areas of focus.
No specific findings, outcomes, or conclusions from the study have been provided beyond the title and publication details. This brief does not characterize or summarize any results, efficacy data, or safety data associated with the study, as none were supplied.
Readers interested in further detail should consult the original publication directly. For general background on cetrorelix, see the compound overview.